On this page
3-hydroxy-3-methylglutaryl-CoA lyase deficiency
This rare condition affects the body's energy production, especially during fasting or illness. It can lead to serious health issues if not managed, primarily impacting infants and young children through metabolic crises.
Available at Jeen Health
Clinical tests that include this
Overview
3-hydroxy-3-methylglutaryl-CoA lyase deficiency (HMGCL deficiency) is a rare, inherited metabolic disorder. Individuals with this condition have difficulty breaking down specific amino acids (components of protein) and fatty acids. This process is essential for the body to produce energy, particularly when food intake is low, such as during prolonged fasting or illness [PMID:37517036].
When the body cannot properly process these substances, harmful by-products can build up, and the body's energy stores become depleted. Without adequate energy, especially in the brain and other vital organs, serious health problems can arise. The condition is part of a group of disorders known as inborn errors of metabolism (IEMs), which are typically identified through newborn screening programmes in the UK.
HMGCL deficiency is estimated to affect around 1 in 100,000 live births globally. Early diagnosis and careful management are crucial to prevent severe complications and improve long-term outcomes for affected individuals.
Symptoms & clinical features
The symptoms of HMGCL deficiency often appear in infancy or early childhood, typically during periods of metabolic stress such as fasting, infections, or vomiting. Common signs include poor feeding, vomiting, lethargy, irritability, and muscle weakness (hypotonia). Some infants may experience seizures [PMID:32761845].
A characteristic feature of a metabolic crisis in HMGCL deficiency is a sudden drop in blood sugar levels (hypoglycaemia) and a build-up of acid in the blood (metabolic acidosis). This can also be accompanied by an excess of ammonia in the blood (hyperammonaemia). If these symptoms are not recognised and treated promptly, they can lead to more severe complications, including coma and potentially life-threatening organ damage.
Less commonly, some individuals may have a milder presentation, with symptoms only appearing later in childhood or even adulthood, often triggered by severe physiological stress. However, severe episodes in infancy are most typical.
Video: Genetics 101
Affected organs
HMGCL deficiency primarily affects organs that have high energy demands or are involved in metabolic waste processing. The brain is particularly vulnerable to energy depletion and the build-up of toxic metabolites; this can lead to neurological symptoms such as developmental delay, seizures, and in severe cases, brain damage.
The liver also plays a crucial role in metabolism and can be affected, sometimes showing signs of liver dysfunction. Muscle weakness (hypotonia) indicates an impact on the muscular system, and the overall metabolic disturbance can affect multiple body systems, leading to a general decline in health during metabolic crises.
Risks & severity
The severity of HMGCL deficiency can vary considerably, but it is generally considered a severe condition if left untreated. The most significant risks are metabolic crises, which are medical emergencies. These crises can be triggered by common childhood illnesses, prolonged fasting, or any physiological stress that increases energy demands [PMID:37517036].
Repeated or prolonged metabolic crises can lead to permanent neurological damage, developmental delay, and intellectual disability. In severe cases, especially in newborns or infants, HMGCL deficiency can be life-threatening. With early diagnosis, typically through newborn screening, and consistent management, many individuals can avoid severe complications and lead relatively healthy lives.
Genetic causes
HMGCL deficiency is caused by pathogenic variants in the HMGCL gene. This gene provides instructions for making an enzyme called 3-hydroxy-3-methylglutaryl-CoA lyase (HMG-CoA lyase). This enzyme is crucial for breaking down leucine, an amino acid found in proteins, and certain fatty acids.
Specifically, HMG-CoA lyase plays a vital role in two metabolic pathways: ketogenesis (the production of ketone bodies, which are alternative fuel sources during fasting) and the breakdown of leucine. When pathogenic variants in HMGCL disrupt the function of this enzyme, the body cannot effectively produce ketones or fully break down leucine and certain fatty acids. This leads to an accumulation of toxic intermediates and a lack of energy, particularly ketone bodies, during times of metabolic need [PMID:32761845].
- HMGCL 3-hydroxy-3-methylglutaryl-CoA lyaseThe HMGCL gene provides instructions for an enzyme crucial in breaking down proteins and fats, particularly during periods of fasting.
Inheritance pattern
HMGCL deficiency is inherited in an autosomal recessive pattern. This means that a child must inherit two copies of a pathogenic HMGCL gene variant - one from each parent - to develop the condition.
Parents who each carry one copy of a pathogenic variant are known as carriers. Carriers typically do not show any symptoms of the condition themselves because they have one working copy of the gene. For each pregnancy, if both parents are carriers, there is a 1 in 4 (25%) chance that their child will inherit two pathogenic variants and be affected by HMGCL deficiency, a 1 in 2 (50%) chance that their child will be a carrier like them, and a 1 in 4 (25%) chance that their child will inherit two unaffected gene copies and not be a carrier.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
Diagnosis & testing
Diagnosis of HMGCL deficiency often begins with newborn screening in the UK, which can detect specific metabolic markers in a blood spot sample. If initial screening results suggest HMGCL deficiency, further diagnostic tests are carried out.
These confirmatory tests typically include specialised urine organic acid analysis and blood acylcarnitine analysis, which can identify the characteristic build-up of specific metabolites. The definitive diagnosis is confirmed through genetic testing, which involves analysing the HMGCL gene for pathogenic variants. Genetic testing for inborn errors of metabolism is often performed via the NHS Genomic Medicine Service (GMS) pathways, with referrals made by paediatricians or clinical geneticists, typically using relevant R-codes for metabolic disorders.
Management & lifestyle
Management of HMGCL deficiency focuses on preventing metabolic crises and maintaining stable energy levels. This primarily involves a carefully controlled diet that limits protein intake (especially leucine) and provides sufficient carbohydrates to prevent fasting.
Dietary management is usually overseen by a specialist metabolic dietitian. During times of illness, or if unable to eat, individuals may require urgent medical attention, often involving intravenous glucose administration to prevent hypoglycaemia and metabolic acidosis. Regular monitoring of metabolic markers may also be part of the management plan.
Individuals are typically managed by a specialist metabolic team, often based at a regional metabolic centre, and supported by genetic counsellors who can provide information about the genetic aspects of the condition and its implications for family planning.
UK care pathway
In the UK, individuals with suspected or confirmed HMGCL deficiency are managed within the NHS Genomic Medicine Service (GMS) framework. Newborn screening programmes aim to identify affected individuals early, allowing for timely intervention.
Referral pathways typically involve paediatricians and clinical geneticists, who can order confirmatory genetic testing through the GMS using relevant R-codes for metabolic conditions. Following diagnosis, care is usually coordinated by specialist metabolic centres, providing access to multidisciplinary teams including dietitians, metabolic consultants, and genetic counsellors. Genetic counsellors offer crucial support, helping families understand the inheritance pattern and implications for other family members.
Frequently asked questions
What is the life expectancy for someone with HMGCL deficiency?
With early diagnosis, strict adherence to dietary management, and prompt treatment during metabolic crises, individuals with HMGCL deficiency can often have a normal or near-normal life expectancy. Untreated or poorly managed cases can lead to severe complications and reduced life expectancy.
Can HMGCL deficiency be cured?
Currently, there is no cure for HMGCL deficiency. However, it is a manageable condition. Treatment focuses on preventing symptoms and complications through dietary control and close medical supervision, rather than curing the underlying genetic cause.
How is HMGCL deficiency diagnosed in the UK?
In the UK, HMGCL deficiency is often first suspected through the NHS newborn screening programme. If the screening test is abnormal, further blood and urine tests are conducted, and the diagnosis is confirmed by genetic testing of the HMGCL gene through the NHS Genomic Medicine Service.
What support is available for families affected by HMGCL deficiency?
Families affected by HMGCL deficiency can access support through specialist metabolic teams within the NHS, including metabolic consultants and dietitians. Genetic counsellors provide information on inheritance, and patient support groups can offer valuable peer support and resources. Your clinical team can provide details on local and national support services.
Are there any alternative treatments for HMGCL deficiency?
The primary and most effective treatment for HMGCL deficiency is dietary management, involving a restricted protein intake and careful carbohydrate supplementation, particularly during illness. Other 'alternative' treatments are not typically recommended as they lack scientific evidence and could be harmful, potentially interfering with established medical care.
References
- Ploechl E, Bachmann C, Colombo JP. 3-Hydroxy-3-methylglutaryl-CoA-lyase deficiency. Journal of inherited metabolic disease. 1989. PMID: 2515385
- Martín-Rivada Á, Palomino Pérez L, Ruiz-Sala P. Diagnosis of inborn errors of metabolism within the expanded newborn screening in the Madrid region. JIMD reports. 2022. PMID: 35281663
- Walter JH, Clayton PT, Leonard JV. 3-Hydroxy-3-methylglutaryl-CoA lyase deficiency. Journal of inherited metabolic disease. 1986. PMID: 3099075
- Gibson KM, Lee CF, Hoffmann GF. Screening for defects of branched-chain amino acid metabolism. European journal of pediatrics. 1994. PMID: 7957389
- Václavík J, Mádrová L, Kouřil Š. A newborn screening approach to diagnose 3-hydroxy-3-methylglutaryl-CoA lyase deficiency. JIMD reports. 2020. PMID: 32685354
- Al-Sayed M, Imtiaz F, Alsmadi OA. Mutations underlying 3-hydroxy-3-methylglutaryl CoA lyase deficiency in the Saudi population. BMC medical genetics. 2006. PMID: 17173698
- de Sousa J, Vencálek O, Hron K. Bayesian multiple hypotheses testing in compositional analysis of untargeted metabolomic data. Analytica chimica acta. 2020. PMID: 31910969
- Wysocki SJ, Hähnel R. 3-Hydroxy-3-methylglutaryl-coenzyme a lyase deficiency: a review. Journal of inherited metabolic disease. 1986. PMID: 3099065